Display options
Cite
Turk H, Celik O, Un S, et al. Predictive factors for biochemical recurrence in radical prostatectomy patients. Cent European J Urol. 2015;68(4):404-9doi: 10.5173/ceju.2015.606.
Turk, H., Celik, O., Un, S., Yoldas, M., İsoglu, C. S., Karabicak, M., Ergani, B., Koc, G., Zorlu, F., & Ilbey, Y. O. (2015). Predictive factors for biochemical recurrence in radical prostatectomy patients. Central European journal of urology, 68(4), 404-9. https://doi.org/10.5173/ceju.2015.606
Turk, Hakan, et al. "Predictive factors for biochemical recurrence in radical prostatectomy patients." Central European journal of urology vol. 68,4 (2015): 404-9. doi: https://doi.org/10.5173/ceju.2015.606
Turk H, Celik O, Un S, Yoldas M, İsoglu CS, Karabicak M, Ergani B, Koc G, Zorlu F, Ilbey YO. Predictive factors for biochemical recurrence in radical prostatectomy patients. Cent European J Urol. 2015;68(4):404-9. doi: 10.5173/ceju.2015.606. Epub 2015 Nov 30. PMID: 26855791; PMCID: PMC4742437.
Copy Download .nbib Format: NLM
Share it on

Cent European J Urol. 2015;68(4):404-9. doi: 10.5173/ceju.2015.606. Epub 2015 Nov 30.

Predictive factors for biochemical recurrence in radical prostatectomy patients.

Central European journal of urology

Hakan Turk, Orcun Celik, Sitki Un, Mehmet Yoldas, Cemal Selcuk İsoglu, Mustafa Karabicak, Batuhan Ergani, Gokhan Koc, Ferruh Zorlu, Yusuf Ozlem Ilbey

Affiliations

  1. Tepecik Teaching and Research Hospital, Department of Urology, Izmir, Turkey.
  2. Katip Celebi University Medical School Hospital, Izmir, Turkey.

PMID: 26855791 PMCID: PMC4742437 DOI: 10.5173/ceju.2015.606

Abstract

INTRODUCTION: Radical prostatectomy (RP) is considered the best treatment for the management of localized prostate cancer in patients with life expectancy over 10 years. However, a complete recovery is not guaranteed for all patients who received/underwent RP treatment. Biochemical recurrence is frequently observed during the post-operative follow-up period. The main objective in this study is to evaluate the predictive factors of biochemical recurrence in localized prostate cancer patients who underwent RP surgery.

MATERIAL AND METHODS: The study included 352 patients with prostate cancer treated by RP at a single institution between February 2004 and June 2014. Detailed pathological and follow-up data of all patients were obtained and analyzed to determine the results.

RESULTS: Mean follow-up duration was 39.7 months. 83 patients (23%) experienced biochemical recurrence (BCR) during the follow-up period. Mean BCR duration range was 6.56 (1-41) months. In multivariate logistic regression analysis, Gleason score (GS), PSA and extra-capsular tumour spread (ECS) variables were found to be statistically significant as BCR predictive factors.

CONCLUSIONS: According to our study results, it is thought that PSA, GS and ECS can all be used for guidance in choosing a treatment modality for post-RP biochemical recurrence and metastatic disease as predictive factors. However, there is no consensus in this matter and it is still debated.

Keywords: Gleason score; prostate cancer; radical prostatectomy; recurrence

References

  1. Korean J Urol. 2010 Nov;51(11):745-51 - PubMed
  2. Urology. 1996 Aug;48(2):249-60 - PubMed
  3. J Urol. 1997 Oct;158(4):1452-6 - PubMed
  4. Arch Pathol Lab Med. 2000 Jul;124(7):995-1000 - PubMed
  5. Urology. 1995 May;45(5):831-8 - PubMed
  6. J Urol. 2010 Oct;184(4):1341-6 - PubMed
  7. Urology. 2003 Aug;62(2):304-9 - PubMed
  8. Urology. 1994 May;43(5):649-59 - PubMed
  9. BJU Int. 2013 Mar;111(3 Pt B):E24-9 - PubMed
  10. Cancer. 2004 Apr 15;100(8):1633-8 - PubMed
  11. J Urol. 1995 Oct;154(4):1447-52 - PubMed
  12. J Urol. 2008 May;179(5 Suppl):S47-51 - PubMed
  13. J Urol. 1993 May;149(5):1040-5 - PubMed
  14. BJU Int. 2010 Feb;105(3):322-8 - PubMed
  15. Urology. 1993 Dec;42(6):622-9 - PubMed
  16. Urol Clin North Am. 2001 Aug;28(3):555-65 - PubMed
  17. J Urol. 2010 May;183(5):1786-91 - PubMed
  18. J Natl Cancer Inst. 1996 Feb 21;88(3-4):166-73 - PubMed
  19. J Urol. 2006 Jan;175(1):140-4; discussion 144-5 - PubMed
  20. CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 - PubMed
  21. Mod Pathol. 2008 Sep;21(9):1095-100 - PubMed
  22. Urology. 2003 Feb;61(2):365-9 - PubMed
  23. Int Braz J Urol. 2014 May-Jun;40(3):306-15 - PubMed
  24. BJU Int. 2012 Jun;109(11):1614-9 - PubMed
  25. J Urol. 2009 Nov;182(5):2291-5 - PubMed
  26. Ann Oncol. 2005 Mar;16(3):481-8 - PubMed
  27. Urology. 2009 Dec;74(6):1289-95 - PubMed
  28. Hum Pathol. 1998 Aug;29(8):856-62 - PubMed
  29. Can Urol Assoc J. 2015 May-Jun;9(5-6):E252-5 - PubMed
  30. BJU Int. 2002 Jul;90(2):162-73 - PubMed
  31. J Urol. 2004 Sep;172(3):910-4 - PubMed
  32. Urology. 2004 Feb;63(2):333-6 - PubMed
  33. J Urol. 2001 Jan;165(1):126-9 - PubMed
  34. Int Urol Nephrol. 1999;31(1):83-7 - PubMed
  35. Eur J Cancer. 2001 Jan;37(1):83-92 - PubMed
  36. Curr Opin Urol. 2012 May;22(3):237-42 - PubMed
  37. J Natl Cancer Inst. 1968 Jan;40(1):43-68 - PubMed
  38. J Clin Oncol. 1999 May;17(5):1499-507 - PubMed
  39. BJU Int. 2013 May;111(5):723-30 - PubMed
  40. Hinyokika Kiyo. 2005 Apr;51(4):241-6 - PubMed
  41. Eur Urol. 2012 Aug;62(2):195-200 - PubMed
  42. Int Braz J Urol. 2011 May-Jun;37(3):328-34; discussion 334-5 - PubMed
  43. Scand J Urol. 2013 Dec;47(6):443-8 - PubMed
  44. J Urol. 2000 Jul;164(1):101-5 - PubMed
  45. Int J Clin Pract. 2004 Apr;58(4):382-90 - PubMed
  46. Prostate. 1995 Jul;27(1):13-7 - PubMed
  47. JAMA. 1998 Sep 16;280(11):969-74 - PubMed

Publication Types